Costs of patients with chronic kidney disease in Germany.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
06
2019
accepted:
23
03
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
9
7
2020
Statut:
epublish
Résumé
This study aimed to determine the costs and distribution of healthcare spending of patients with chronic kidney disease (CKD) at stages 3 and 4 and on dialysis both at the individual and population level in Germany. The study took the perspective of the German statutory health insurance (SHI) system and analyzed claims data on 3,687,015 insurees from the year 2014. To extrapolate costs to the whole SHI population, a literature search on the prevalence of CKD was conducted. Average costs per person per year in an age- and gender-matched control group of the normal population were €2,876 (95% confidence interval [CI], €2,798 to €2,955) and ≥2.8-fold higher in CKD patients (€8,030 [95% CI, €7,848 to €8,212] at CKD stage 3, €9,760 [95% CI, €9,266 to €10,255] at CKD stage 4, and €44,374 [95% CI, €43,608 to €45,139] on dialysis). At CKD stages 3 and 4 the major cost driver was hospitalizations, contributing to more than 50% of total expenditures. Among dialysis patients, hospitalizations and dialysis-treatment costs contributed to 23% and 53% of total healthcare spending, respectively. At CKD stages 3 and 4, patients with the highest 20% of healthcare spending showed a considerable increase in per-patient costs over the reference population, while the bottom 80% of patients generated only moderately higher per-patient costs (p < 0.001). Comparing total CKD costs to total SHI expenditures yields that 10.2% of SHI expenditures was driven by patients at CKD stages 3 and 4 and 1.6% by dialysis patients. Healthcare spending of patients with CKD at stages 3 and 4 and on dialysis is concentrated among a small number of high-need patients. As hospitalizations and dialysis treatment are key drivers of total expenditures, strategies that lead to a reduction in hospitalizations, delay in dialysis onset, or increase in the availability of kidney donors should become important considerations by policymakers.
Sections du résumé
BACKGROUND
This study aimed to determine the costs and distribution of healthcare spending of patients with chronic kidney disease (CKD) at stages 3 and 4 and on dialysis both at the individual and population level in Germany.
METHODS
The study took the perspective of the German statutory health insurance (SHI) system and analyzed claims data on 3,687,015 insurees from the year 2014. To extrapolate costs to the whole SHI population, a literature search on the prevalence of CKD was conducted.
RESULTS
Average costs per person per year in an age- and gender-matched control group of the normal population were €2,876 (95% confidence interval [CI], €2,798 to €2,955) and ≥2.8-fold higher in CKD patients (€8,030 [95% CI, €7,848 to €8,212] at CKD stage 3, €9,760 [95% CI, €9,266 to €10,255] at CKD stage 4, and €44,374 [95% CI, €43,608 to €45,139] on dialysis). At CKD stages 3 and 4 the major cost driver was hospitalizations, contributing to more than 50% of total expenditures. Among dialysis patients, hospitalizations and dialysis-treatment costs contributed to 23% and 53% of total healthcare spending, respectively. At CKD stages 3 and 4, patients with the highest 20% of healthcare spending showed a considerable increase in per-patient costs over the reference population, while the bottom 80% of patients generated only moderately higher per-patient costs (p < 0.001). Comparing total CKD costs to total SHI expenditures yields that 10.2% of SHI expenditures was driven by patients at CKD stages 3 and 4 and 1.6% by dialysis patients.
CONCLUSIONS
Healthcare spending of patients with CKD at stages 3 and 4 and on dialysis is concentrated among a small number of high-need patients. As hospitalizations and dialysis treatment are key drivers of total expenditures, strategies that lead to a reduction in hospitalizations, delay in dialysis onset, or increase in the availability of kidney donors should become important considerations by policymakers.
Identifiants
pubmed: 32330140
doi: 10.1371/journal.pone.0231375
pii: PONE-D-19-16720
pmc: PMC7182232
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231375Déclaration de conflit d'intérêts
WA, WW, and UT are employed by Fresenius Medical Care. JM is employed by Elsevier Health Analytics. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Références
Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii73-80
pubmed: 22815543
BMC Nephrol. 2017 Nov 28;18(1):341
pubmed: 29183273
J Am Soc Nephrol. 2019 Oct;30(10):1991-1999
pubmed: 31492808
BMC Nephrol. 2015 Apr 29;16:65
pubmed: 25924679
Dtsch Med Wochenschr. 2017 Sep;142(17):1276-1281
pubmed: 28850964
J Nephrol. 2017 Dec;30(6):787-793
pubmed: 28303461
Prev Med. 2009 Feb;48(2):122-7
pubmed: 19041887
Nephrol Dial Transplant. 2010 May;25(5):1647-52
pubmed: 20008830
J Health Econ. 2018 Jan;57:60-74
pubmed: 29182935
Am J Manag Care. 2017 Jun;23(10 Suppl):S163-S172
pubmed: 28978205
Semin Nephrol. 2016 Jul;36(4):319-30
pubmed: 27475662
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):341-7
pubmed: 25434825
Kidney Blood Press Res. 2015;40(3):231-43
pubmed: 25966897
PLoS One. 2011;6(10):e25920
pubmed: 22039429
BMJ Open. 2016 Oct 7;6(10):e012062
pubmed: 27855091
Lancet. 2017 Aug 26;390(10097):882-897
pubmed: 28684025
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
J Nephrol. 2017 Apr;30(2):263-269
pubmed: 27165160
Nat Rev Nephrol. 2017 Jul;13(7):393-409
pubmed: 28555652
Eur J Health Econ. 2017 Sep;18(7):847-858
pubmed: 27699568
Int J Health Care Finance Econ. 2007 Sep;7(2-3):185-200
pubmed: 17701342
Am J Nephrol. 2010;31(3):222-9
pubmed: 20068286